title: CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
abstract: CD160, a glycosylphosphatidylinositol-anchored member of the immunoglobulin superfamily, is expressed on both cytolytic lymphocytes and some unstimulated CD4+ T cells. Here we show that CD160 expression was increased after activation of human CD4+ T cells and that crosslinking CD160 with monoclonal antibody strongly inhibited CD3- and CD28-mediated activation. We found that herpesvirus entry mediator (HVEM) was a ligand of CD160 that acted as a 'bidirectional switch' for T cell activation, producing a positive or negative outcome depending on the engagement of HVEM by CD160 and known HVEM ligands such as B and T lymphocyte attenuator (BTLA) and the T lymphocyte receptor LIGHT. Inhibition of CD4+ T cell activation by HVEM-transfected cells was dependent on CD160 and BTLA; when the cysteine-rich domain 1 of HVEM was deleted, this inhibition was lost, resulting in strong T cell activation. CD160 thus serves as a negative regulator of CD4+ T cell activation through its interaction with HVEM.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: Guifang
authors.initials: G
authors.lastname: Cai
authors.forename: Anukanth
authors.initials: A
authors.lastname: Anumanthan
authors.forename: Julia A
authors.initials: JA
authors.lastname: Brown
authors.forename: Edward A
authors.initials: EA
authors.lastname: Greenfield
authors.forename: Baogong
authors.initials: B
authors.lastname: Zhu
authors.forename: Gordon J
authors.initials: GJ
authors.lastname: Freeman
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003001:Cloning, Molecular; D058851:GPI-Linked Proteins; D006801:Humans; D008024:Ligands; D008213:Lymphocyte Activation / Q000187:drug effects; D017434:Protein Structure, Tertiary; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors / Q000378:metabolism*; D053240:Receptors, Tumor Necrosis Factor, Member 14 / Q000235:genetics / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C114505:CD160 protein, human; D058851:GPI-Linked Proteins; D008024:Ligands; D011971:Receptors, Immunologic; D053240:Receptors, Tumor Necrosis Factor, Member 14